Anavex Life Sciences Corp (AVXL)

[falconer66a]

Company Arranges Or Has Funding

thank you. are sufficient funds in hand for all three?..I know that is a somewhat subjective question....in your opinion.

My opinion is this: the company would not be announcing new trials unless they were assured of funding. Whether it’s internal or external (perhaps to a degree), isn’t presently known for the big Alzheimer’s trial.

But the Rett Foundation appears to be at least a partial funder of that trial. Same with the Michael J. Fox Foundation for the Parkinson’s trial.

Anavex critics and skeptics will turn right around and claim none of these assertions are supported by actual posted funding numbers, etc. Those who embrace such views are welcome to them—and shouldn’t buy or own a share of AVXL until positive trial results are completed and released for all three diseases.

Of course, if and when that happens, the share price of AVXL will be much greater.

Again, this is a small pharmaceutical start up, with no current sales revenues. Those of us with small to moderate AVXL positions have taken them for several, co-supporting reasons:

1. The pre-clinical and early clinical data for Anavex 2-73, against Alzheimer’s disease, are quite phenomenal; requiring the final one-year double-blind clinical trial for regulatory affirmation. No other drug, on the market or in equivalent human testing has exhibited such remarkable symptom stability or suppression. All others end up with their patients declining. Anavex patients stayed at start-of-trial baselines, or even got better.

2. Those data and results are supported by the unique and strong chemical pathway mechanisms of action unique to Anavex 2-73. Anavex science is solid. No other drug shows the ability to restore neuron function in the manner of, or to the degree of Anavex 2-73.

3. The early Phase 1/ Phase 2 safety and tolerability study in Australia substantiated lab animal studies, revealing no adverse events (side effects) of any negating consequence.

4. Likewise, Anavex 2-73 can be administered orally, whereby it efficiently crosses the blood/brain barrier; facilitating treatment without injection or infusion.

Lastly, I haven’t bet my ranch (or retirement) with such funds to buy my AVXL position. Should Anavex Life Sciences Corp fail, I’ve lost funds that I allocated and knew from the start were discretionary. Life will continue, no matter. If Anavex proves to be the new pharmaceutical I’ve envisioned, I will be handsomely rewarded. (Moreover, millions of people around the world will live longer, healthy lives, undeterred by the costs and pains of the diseases the drugs in the Anavex pipeline will target.)